Beyond Semaglutide, a Coming Pipeline of New Antiobesity Meds
With nutrient-stimulated hormone therapies for obesity in phase 3 trials, and activin-receptor inhibitors the next upcoming drug class, highly effective treatments for obesity are in sight.